Johnson & Johnson (JNJ)
250.61
0.00 (0.00%)
Upcoming Events
Latest Headlines
FDA clears Johnson & Johnson's Ottava robotic surgical system
July 22, 2026 7:01 AM - StreetInsider
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
July 22, 2026 7:00 AM - BizWire
Form 4 JOHNSON & JOHNSON For: Jul 20 Filed by: Broadhurst Vanessa
July 21, 2026 5:28 PM - SEC Filing
Form 144 JOHNSON & JOHNSON Filed by: Broadhurst Vanessa
July 20, 2026 1:35 PM - SEC Filing
Johnson & Johnson (JNJ) PT Raised to $276 at Leerink
July 17, 2026 8:36 AM - StreetInsider
Freedom Capital Upgrades Johnson & Johnson (JNJ) to Buy
July 16, 2026 1:27 PM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $270 at JPMorgan
July 16, 2026 8:49 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $261 at Bernstein SocGen
July 16, 2026 8:46 AM - StreetInsider
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
July 16, 2026 8:11 AM - BizWire
DePuy Synthes acquires expandable spine implant maker
July 16, 2026 8:00 AM - StreetInsider
DePuy Synthes Acquires Expanding Innovations™
July 16, 2026 8:00 AM - BizWire
Johnson & Johnson (JNJ) PT Raised to $294 at Morgan Stanley
July 16, 2026 7:51 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $305 at Scotiabank
July 16, 2026 7:13 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $272 at Wells Fargo
July 16, 2026 6:56 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
July 16, 2026 6:40 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $260 at Stifel
July 15, 2026 3:35 PM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Jul 15
July 15, 2026 7:49 AM - SEC Filing
Johnson & Johnson beats estimates but shares dip
July 15, 2026 6:56 AM - StreetInsider
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
July 15, 2026 6:25 AM - BizWire
Johnson & Johnson (JNJ) Declares $1.34 Quarterly Dividend; 2.1% Yield
July 15, 2026 6:25 AM - StreetInsider
Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance
July 15, 2026 6:21 AM - StreetInsider
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
July 15, 2026 6:20 AM - BizWire
Johnson & Johnson Q2 earnings preview: analysts eye product launch progress
July 15, 2026 3:00 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 1.6 calls to 1 put into quarter results
July 14, 2026 11:28 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 1.5 calls to 1 put into quarter results
July 14, 2026 6:41 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 2.8 calls to 1 put into quarter results
July 13, 2026 11:09 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $300 at TD Cowen
July 13, 2026 8:49 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $287 at RBC Capital
July 13, 2026 7:13 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $284 at Morgan Stanley
July 8, 2026 8:08 AM - StreetInsider
FDA clears Johnson & Johnson dual-energy cardiac ablation catheter
July 8, 2026 7:45 AM - StreetInsider
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
July 8, 2026 7:45 AM - BizWire
Increasing unusual put volume: AEVA SOLS LI TAP MTUM VSAT CMPS FPS CBRL JNJ NTAP
July 7, 2026 10:31 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $290 at HSBC
July 6, 2026 1:35 AM - StreetInsider
Increasing unusual put volume: XLI EQT ARKG ROST WEN KOS BKLN UUP DB DJ JNJ LOW FVRR
July 2, 2026 10:29 AM - StreetInsider
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026 9:00 AM - StreetInsider
DePuy Synthes names Christina Zamarro as CFO, effective July 2026
June 29, 2026 4:33 PM - StreetInsider
J&J presents new IMAAVY data for myasthenia gravis at EAN 2026
June 26, 2026 12:35 PM - StreetInsider
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
June 26, 2026 12:35 PM - PR NewsWire
Johnson & Johnson (JNJ) PT Raised to $270 at Guggenheim
June 26, 2026 7:38 AM - StreetInsider
Form 11-K JOHNSON & JOHNSON For: Dec 31
June 25, 2026 5:16 PM - SEC Filing
Form 11-K JOHNSON & JOHNSON For: Dec 31
June 25, 2026 5:13 PM - SEC Filing
Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
June 17, 2026 11:15 AM - StreetInsider
Johnson & Johnson invests $1 billion in Jacksonville vision manufacturing
June 15, 2026 6:01 AM - StreetInsider
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
June 15, 2026 6:00 AM - BizWire
Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
June 14, 2026 2:01 PM - StreetInsider
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple my
June 13, 2026 6:34 AM - PR NewsWire
Form 4 JOHNSON & JOHNSON For: Jun 11 Filed by: Wengel Kathryn E
June 12, 2026 5:24 PM - SEC Filing
Leerink highlights drug demand rebound after Memorial Day
June 12, 2026 2:42 PM - StreetInsider
Form 4 JOHNSON & JOHNSON For: Jun 09 Filed by: Woods Eugene A.
June 11, 2026 4:57 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Jun 09 Filed by: Pinto Daniel E
June 11, 2026 4:44 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Jun 09 Filed by: HEWSON MARILLYN A
June 11, 2026 4:36 PM - SEC Filing
Form 144 JOHNSON & JOHNSON Filed by: Wengel Kathryn E
June 11, 2026 1:44 PM - SEC Filing
Johnson & Johnson expands US availability of TECNIS PureSee IOL
June 11, 2026 7:45 AM - StreetInsider
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
June 11, 2026 7:45 AM - BizWire
Johnson & Johnson reports positive results for rare blood disorder treatment
June 11, 2026 7:43 AM - StreetInsider
Johnson & Johnson drug shows positive results for rare blood condition
June 11, 2026 2:03 AM - StreetInsider
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease wi
June 11, 2026 2:03 AM - PR NewsWire
Johnson & Johnson faces $32 million verdict in Los Angeles asbestos case
June 10, 2026 11:22 AM - StreetInsider
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
June 10, 2026 11:22 AM - BizWire
Johnson & Johnson to acquire Firefly Bio for $1 billion in cash
June 8, 2026 8:00 AM - StreetInsider
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
June 8, 2026 8:00 AM - BizWire
Johnson & Johnson reports nipocalimab shows stronger response in Sjögren's patients
June 3, 2026 3:14 AM - StreetInsider
Johnson & Johnson's nipocalimab meets primary endpoint in lupus trial
June 3, 2026 12:04 AM - StreetInsider
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
June 3, 2026 12:04 AM - PR NewsWire
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
June 3, 2026 12:03 AM - PR NewsWire
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
May 31, 2026 8:30 AM - PR NewsWire
J&J prostate cancer drug shows positive trial results before surgery
May 31, 2026 8:28 AM - StreetInsider
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradi
May 31, 2026 8:27 AM - PR NewsWire
J&J's RYBREVANT plus LAZCLUZE shows 3.5-year survival in lung cancer study
May 29, 2026 2:00 PM - StreetInsider
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
May 29, 2026 2:00 PM - PR NewsWire
Johnson & Johnson TECVAYLI shows survival benefits in myeloma study
May 29, 2026 8:41 AM - StreetInsider
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
May 29, 2026 8:18 AM - PR NewsWire
FDA approves expanded TREMFYA label for joint damage prevention
May 28, 2026 7:10 PM - StreetInsider
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
May 28, 2026 7:10 PM - PR NewsWire
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
May 27, 2026 4:22 PM - BizWire
Form SD JOHNSON & JOHNSON
May 27, 2026 4:16 PM - SEC Filing
DePuy Synthes signs exclusive distribution deal with CGBIO for bone graft
May 26, 2026 8:03 AM - StreetInsider
DePuy Synthes acquires radiofrequency tracking technology for joint surgery
May 26, 2026 8:01 AM - StreetInsider
DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across its Joint Reconstruction Portfolio
May 26, 2026 8:01 AM - BizWire
DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS
May 26, 2026 8:00 AM - BizWire
FDA approves accord Biopharma's Immgolis, a biosimilar to Simponi
May 15, 2026 2:58 PM - StreetInsider
Johnson & Johnson survey finds bladder cancer treatments impact patient quality of life
May 14, 2026 4:01 PM - StreetInsider
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
May 14, 2026 4:01 PM - PR NewsWire
Form 13F-HR JOHNSON & JOHNSON For: Mar 31
May 13, 2026 4:30 PM - SEC Filing
JNJ gets Wall Street boost as blockbuster drug bets ignite growth hopes
May 13, 2026 10:56 AM - StreetInsider
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
May 13, 2026 8:30 AM - Globe NewsWire
Leerink Partners Upgrades Johnson & Johnson (JNJ) to Outperform
May 13, 2026 6:10 AM - StreetInsider
Johnson & Johnson launches Shockwave C2 Aero coronary catheter globally
May 12, 2026 7:45 AM - StreetInsider
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
May 12, 2026 7:45 AM - BizWire
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 11, 2026 4:34 PM - BizWire
Johnson & Johnson presents neuropsychiatry data at medical conferences
May 11, 2026 8:01 AM - StreetInsider
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
May 11, 2026 8:00 AM - PR NewsWire
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
May 7, 2026 8:00 AM - PR NewsWire
Protagonist Therapeutics (PTGX) PT Raised to $137 at Citizens
May 6, 2026 4:28 AM - StreetInsider
Johnson & Johnson's TREMFYA shows efficacy in perianal fistulizing Crohn's
May 5, 2026 8:05 AM - StreetInsider
Johnson & Johnson reports positive phase 2b results for experimental IBD therapy
May 5, 2026 8:05 AM - StreetInsider
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
May 5, 2026 8:05 AM - PR NewsWire
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
May 5, 2026 8:05 AM - PR NewsWire
Johnson & Johnson reports clinical trial results for robotic surgery system
May 5, 2026 7:00 AM - StreetInsider
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
May 5, 2026 7:00 AM - BizWire
Form 4 JOHNSON & JOHNSON For: May 01 Filed by: REED JOHN C
May 4, 2026 4:59 PM - SEC Filing
Johnson & Johnson presents CAPLYTA analysis for depression treatment
May 4, 2026 8:03 AM - StreetInsider
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
May 4, 2026 8:00 AM - PR NewsWire
Form SCHEDULE 13G JOHNSON & JOHNSON Filed by: VANGUARD CAPITAL MANAGEMENT LLC
May 1, 2026 9:12 AM - SEC Filing
Johnson & Johnson names Ryan Koors as VP of investor relations
April 30, 2026 8:02 AM - StreetInsider
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
April 30, 2026 8:02 AM - BizWire
Form 8-K JOHNSON & JOHNSON For: Apr 23
April 28, 2026 6:01 AM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Woods Eugene A.
April 27, 2026 6:24 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: West Nadja
April 27, 2026 6:22 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: WEINBERGER MARK A
April 27, 2026 6:17 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Pinto Daniel E
April 27, 2026 6:14 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: MORIKIS JOHN G
April 27, 2026 6:12 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: McClellan Mark B.
April 27, 2026 6:07 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Joly Hubert
April 27, 2026 6:06 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Johnson Paula A
April 27, 2026 6:01 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: HEWSON MARILLYN A
April 27, 2026 5:49 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Doudna Jennifer A
April 27, 2026 5:43 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Apr 23 Filed by: Beckerle Mary C
April 27, 2026 5:38 PM - SEC Filing
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference
April 27, 2026 4:33 PM - BizWire
FDA grants priority review to J&J's IMAAVY for rare blood disorder
April 27, 2026 8:03 AM - StreetInsider
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
April 27, 2026 8:03 AM - PR NewsWire
Johnson & Johnson (JNJ) to start marketing 4 meds on TrumpRX - CBS
April 24, 2026 4:23 PM - StreetInsider
Johnson & Johnson to acquire medical device firm Atraverse Medical
April 24, 2026 8:38 AM - StreetInsider
Full Article List
